583 related articles for article (PubMed ID: 32715279)
1. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
Sanders O; Rajagopal L
J Alzheimers Dis Rep; 2020 Jun; 4(1):185-215. PubMed ID: 32715279
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review.
Sanders O
J Alzheimers Dis Rep; 2020 Apr; 4(1):91-106. PubMed ID: 32467879
[TBL] [Abstract][Full Text] [Related]
3. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions.
Kang BW; Kim F; Cho JY; Kim S; Rhee J; Choung JJ
Alzheimers Res Ther; 2022 Jul; 14(1):92. PubMed ID: 35804462
[TBL] [Abstract][Full Text] [Related]
5. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Prickaerts J; Heckman PRA; Blokland A
Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like effects of the phosphodiesterase-4 inhibitor etazolate and phosphodiesterase-5 inhibitor sildenafil via cyclic AMP or cyclic GMP signaling in mice.
Wang C; Zhang J; Lu Y; Lin P; Pan T; Zhao X; Liu A; Wang Q; Zhou W; Zhang HT
Metab Brain Dis; 2014 Sep; 29(3):673-82. PubMed ID: 24705918
[TBL] [Abstract][Full Text] [Related]
7. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease.
Sheng J; Zhang S; Wu L; Kumar G; Liao Y; Gk P; Fan H
Front Aging Neurosci; 2022; 14():1019187. PubMed ID: 36268188
[TBL] [Abstract][Full Text] [Related]
9. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease.
Ugarte A; Gil-Bea F; García-Barroso C; Cedazo-Minguez Á; Ramírez MJ; Franco R; García-Osta A; Oyarzabal J; Cuadrado-Tejedor M
Neuropathol Appl Neurobiol; 2015 Jun; 41(4):471-82. PubMed ID: 25488891
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial complex I as a therapeutic target for Alzheimer's disease.
Trushina E; Trushin S; Hasan MF
Acta Pharm Sin B; 2022 Feb; 12(2):483-495. PubMed ID: 35256930
[TBL] [Abstract][Full Text] [Related]
11. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice.
Lueptow LM; Zhan CG; O'Donnell JM
Psychopharmacology (Berl); 2016 Feb; 233(3):447-56. PubMed ID: 26525565
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1α.
Zuo L; Li Q; Sun B; Xu Z; Ge Z
Biochem Biophys Res Commun; 2013 Mar; 433(1):52-7. PubMed ID: 23485471
[TBL] [Abstract][Full Text] [Related]
13. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
[TBL] [Abstract][Full Text] [Related]
14. The mitochondrial regulator PGC1α is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure.
Zhu G; Ueda K; Hashimoto M; Zhang M; Sasaki M; Kariya T; Sasaki H; Kaludercic N; Lee DI; Bedja D; Gabrielson M; Yuan Y; Paolocci N; Blanton RM; Karas RH; Mendelsohn ME; O'Rourke B; Kass DA; Takimoto E
FEBS Lett; 2022 Jan; 596(1):17-28. PubMed ID: 34778969
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer's disease.
Tropea MR; Gulisano W; Vacanti V; Arancio O; Puzzo D; Palmeri A
Free Radic Biol Med; 2022 Nov; 193(Pt 2):657-668. PubMed ID: 36400326
[TBL] [Abstract][Full Text] [Related]
16. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
Sharma VK; Singh TG; Singh S
Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway.
Khalifa M; Abdelsalam RM; Safar MM; Zaki HF
Inflammopharmacology; 2022 Dec; 30(6):2477-2488. PubMed ID: 35727381
[TBL] [Abstract][Full Text] [Related]
18. Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α).
Singh S; Simpson RL; Bennett RG
J Biol Chem; 2015 Jan; 290(2):950-9. PubMed ID: 25389293
[TBL] [Abstract][Full Text] [Related]
19. The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling.
Wang G; Chen L; Pan X; Chen J; Wang L; Wang W; Cheng R; Wu F; Feng X; Yu Y; Zhang HT; O'Donnell JM; Xu Y
Oncotarget; 2016 Apr; 7(14):17380-92. PubMed ID: 26980711
[TBL] [Abstract][Full Text] [Related]
20. Pentoxifylline Enhances Antioxidative Capability and Promotes Mitochondrial Biogenesis in D-Galactose-Induced Aging Mice by Increasing Nrf2 and PGC-1
Wang Y; Zhang T; Zhao H; Qi C; Ji X; Yan H; Cui R; Zhang G; Kang Y; Shi G
Oxid Med Cell Longev; 2021; 2021():6695613. PubMed ID: 34257818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
